• Contact quintiles

    Phone:+1 866 267 4479

    Request a Proposal

  • Scientific Symposium

    Quintiles in Hungary celebrated its 10th anniversary in the country by organising a scientific symposium at the National Academy of Science. 

    The event was attended by over 150 clinical investigators, pharmaceutical company representatives and regulators. The expert speakers discussed a range of topics across the drug development process from the pre clinical phases right through to pharmaceutical marketing. Included on the panel was Dr. Dennis Gillings Chairman and Chief Executive of Quintiles who considered how, by working in partnership, the clinical trail needs to be re-invented if the industry as a whole is to continue to develop new and better medicines.

    Dr. Gilllings believes that the clinical trial has been one of the single most important tools to advance medicine for more than 50 years. Data from clinical trials has led the FDA to approve 982 new drugs since 1963, when the modern drug approval process took shape and the value to healthcare has been enormous.

    “We are the first generation to grow up and grow old with the benefits of a huge variety of medicines from cancer chemotherapy to drugs for heart disease and asthma.” Explained Gillings. “ Between 1988 and 2000, new drug introductions accounted for 40% of the observed increase in life expectancy and the impact of new medicines on improved quality of life is equally impressive.”

    A new era of drug discovery is now unfolding. The chemotherapies of the 20th century are giving way to the biotherapies of the 21st. The medicines that change life in the next 50 years will be based on monoclonal antibodies, fusion proteins, stem cells and other new entities.

    To deliver them, Dr. Gillings described how the 1960s-era Path to Approval must become a super highway that is fast, safe, and reaches all the world’s populations. The re-invention of the clinical trial will rank among the most important medical advances of the new century. The future clinical trial will need to inform more about a drug’s mode of action; it will need to provide both efficacy and safety data sooner and ultimately will mean that new medicines are developed faster, cheaper and with less risk to study subjects.

    “We were honoured that so many guests attendee our symposium which celebrated not only of Quintiles’ 10 years in Hungary, but also the contribution Hungary has made overall to global clinical trials and, hence, to the development of many new medicines,” commented Dr. Janos Filakovszky, Managing Director Quintiles Eastern Region and Middle East. ”The illustrious panel of speakers provided a thought provoking insight into the challenges of clinical development.”